What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been described in patients with neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 antibodies (AQP4-IgG). We aimed to identify the proportion of AQP4-IgG-negative NMOSD patients who are seropositive for MOG-IgG. In a cross sectional study, we reviewed all patients seen in the National NMO clinic over the last 4 years (after the availability of MOG-IgG testing), including clinical information, MRI, and antibody tests. 261 unique patients were identified. 132 cases satisfied the 2015 NMOSD diagnostic criteria. Of these, 96 (73%) were AQP4-IgG positive and 36 (27%) were AQP4-IgG negative. These 36 patients were tested for MOG-IgG and 15/36 (42%) tested positive. 20% (25/125) of the patients who did not satisfy NMOSD criteria had MOG-IgG. Approximately half of seronegative NMOSD is MOG-Ig seropositive and one in five of non-NMOSD/non-MS demyelination is MOG-IgG positive. Since MOG-associated demyelinating disease is likely different from AQP4-IgG disease in terms of underlying disease mechanisms, relapse risk and possibly treatment, testing for MOG-IgG in patients with AQP4-IgG-negative NMOSD and other non-MS demyelination may have significant implications to management and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574 · cited 1×
“We also assessed the proportion of patients with optic neuritis and long myelitis who fulfill Wingerchuk 2006 criteria [6] that are MOG-IgG positive, as this is a clinical question often posed.”
Backgroundin cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays
Waters, P. J., McKeon, A., Leite, M. I., Rajasekharan, S., Lennon, V. A., Villalobos, A., Palace, J., Mandrekar, J. N., Vincent, A., Bar-Or, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318248dec1 · Cited by 526 · cited 1×
“Both AQP4-IgG and MOG-IgG were tested using a validated live cell-based assay with high specificity (John Radcliffe Hospital, Oxford, UK) [4, 5].”
Methodin cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0717-1 · Cited by 429 · cited 1×
“86% (13/15) of our patients who satisfy criteria for NMOSD who are MOG-IgG-positive patients have relapsing disease, similar to a recent study [7] who reported that 80% of their MOG-IgG-positive cohort (n = 50) followed a relapsing course.”
ResultMOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390 · cited 1×
“Both AQP4-IgG and MOG-IgG were tested using a validated live cell-based assay with high specificity (John Radcliffe Hospital, Oxford, UK) [4, 5].”
MethodHöftberger, R., Sepulveda, M., Armangue, T., Blanco, Y., Rostásy, K., Cobo Calvo, A., Olascoaga, J., Ramió-Torrentà, L., Reindl, M., Benito-León, J., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514555785 · Cited by 285
Ramanathan, S., Dale, R. C., & Brilot, F. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.12.004 · Cited by 281 · cited 1×
“Antibodies to myelin oligodendrocyte glycoprotein (MOGIgG) have been increasingly reported in a variety of CNS neuroinflammatory conditions including patients with phenotypes typical for NMOSD [3].”
BackgroundEvaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder
Hyun, J., Jeong, I. H., Joung, A., Kim, S., & Kim, H. J. (2016) · Neurology · doi:10.1212/wnl.0000000000002655 · Cited by 89 · cited 1×
“Keywords Neuromyelitis optica · Aquaporin-4 antibodies · Myelin oligodendrocytes glycoprotein Introduction 73–90% of neuromyelitis optica spectrum disorder (NMOSD) patients diagnosed according to the 2015 International panel on NMO diagnosis have aquaporin-4 antibodies (AQP4-IgG) [1, 2].”
BackgroundThe impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates
Hamid, S. H. M., Elsone, L., Mutch, K., Solomon, T., & Jacob, A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516663853 · Cited by 70
Self-citation
Cited by
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
Hor, J. Y., Asgari, N., Nakashima, I., Broadley, S. A., Leite, M. I., Kissani, N., Jacob, A., Marignier, R., Weinshenker, B. G., Paul, F., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00501 · Cited by 413
Self-citationNeuromyelitis optica spectrum disorders
Huda, S., Whittam, D., Bhojak, M., Chamberlain, J., Noonan, C., Jacob, A., & Kneen, R. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-2-169 · Cited by 283
Self-citationKümpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Jarius, S., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-023-11910-z · Cited by 258
Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00888 · Cited by 227
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
Bennett, J. L., Costello, F., Chen, J. J., Petzold, A., Biousse, V., Newman, N. J., & Galetta, S. L. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00187-9 · Cited by 226
Lin, T.-Y., Chien, C., Lu, A., Paul, F., & Zimmermann, H. G. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1982697 · Cited by 16
Retinal changes in double-antibody seronegative neuromyelitis optica spectrum disorders
Oertel, F. C., Zimmermann, H. G., Motamedi, S., Bereuter, C., Manthey, L. M., Ashtari, F., Kafieh, R., Dehghani, A., Pourazizi, M., Pandit, L., et al. (2024) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200273 · Cited by 6
Metadata
- Authors
- Hamid, S. H. M., Whittam, D., Mutch, K., Linaker, S., Solomon, T., Das, K., Bhojak, M., & Jacob, A.
- Venue
- Journal of Neurology
- Published
- 2017-08-24
- Volume
- 264
- Issue
- 10
- Pages
- 2088-2094
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2747647717
- Cited by
- 222
- References
- 10
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.